These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 35333598)
1. Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline Phillips KA; Friedlander ML J Clin Oncol; 2022 Jun; 40(17):1850-1852. PubMed ID: 35333598 [No Abstract] [Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
3. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024 [TBL] [Abstract][Full Text] [Related]
4. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. Kauff ND; Barakat RR J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523 [TBL] [Abstract][Full Text] [Related]
5. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA; JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424 [TBL] [Abstract][Full Text] [Related]
6. Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy. Zhang J; Liu M J Clin Oncol; 2022 Nov; 40(32):3783. PubMed ID: 35820079 [No Abstract] [Full Text] [Related]
7. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174 [TBL] [Abstract][Full Text] [Related]
8. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study. Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701 [TBL] [Abstract][Full Text] [Related]
9. Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. Harao M; Ando J; Kamata H; Hoshi N; Igarashi S; Sekiguchi R; Sugano K Breast Cancer; 2018 Mar; 25(2):243-249. PubMed ID: 29094253 [TBL] [Abstract][Full Text] [Related]
10. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508 [TBL] [Abstract][Full Text] [Related]
12. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
13. Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed. Conduit C; Milne RL; Phillips KA JAMA Oncol; 2021 Sep; 7(9):1401. PubMed ID: 34196653 [No Abstract] [Full Text] [Related]
14. Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply. Choi YH; Terry MB; Briollais L JAMA Oncol; 2021 Sep; 7(9):1402. PubMed ID: 34196652 [No Abstract] [Full Text] [Related]
15. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection. Martelli G; Barretta F; Vernieri C; Folli S; Pruneri G; Segattini S; Trapani A; Carolla C; Spatti G; Miceli R; Ferraris C JAMA Surg; 2023 Dec; 158(12):1275-1284. PubMed ID: 37792368 [TBL] [Abstract][Full Text] [Related]
16. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy. Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055 [TBL] [Abstract][Full Text] [Related]
17. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations. Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390 [TBL] [Abstract][Full Text] [Related]
18. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
19. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435 [TBL] [Abstract][Full Text] [Related]